Wednesday, July 1, 2026

Otsuka completes acquisition of Transcend Therapeutics

Otsuka America, a subsidiary of Otsuka Pharmaceutical, has completed its acquisition of Transcend Therapeutics. The clinical-stage biotechnology company is developing therapies for neuropsychiatric diseases, including a rapid-acting candidate for post-traumatic stress disorder.

Transcend will operate as a wholly owned subsidiary of Otsuka America. The transaction includes 700 million US dollars paid to Transcend shareholders at closing. Further contingent payments of up to 525 million US dollars may become due, depending on future sales linked to development assets.

PTSD candidate moves through late-stage development

The main asset in the deal is TSND-201, also known as methylone. Transcend is developing the investigational candidate as a potential treatment for post-traumatic stress disorder. According to the companies, more than 13 million people in the United States are estimated to be affected by PTSD each year. No new treatment has been approved for the condition in more than 25 years.

TSND-201 is described as a rapid-acting neuroplastogen. The candidate showed favorable results in the Phase 2 IMPACT-1 clinical trial, and a Phase 3 study is now under way to further assess safety and efficacy. The program has received Breakthrough Therapy designation from the US Food and Drug Administration and has been selected for a priority voucher program intended to accelerate access to psychedelic treatments.

Otsuka strengthens CNS strategy

Otsuka frames the acquisition as part of a broader commitment to serious neuropsychiatric conditions. Tarek Rabah, president and CEO of Otsuka North America Pharmaceutical Business, pointed to the combination of Otsuka’s experience in central nervous system disorders and Transcend’s development approach.

Transcend CEO Blake Mandell also linked the transaction to the potential acceleration of clinical development and broader access to future treatment options. Founded in 2021 and based in New York City, Transcend focuses on rapid-acting medicines for neuropsychiatric diseases.

For Otsuka, the deal adds another asset to a series of investments in next-generation approaches for serious mental illness. It also reflects continuing industry interest in neuropsychiatric programs aimed at unmet medical need and novel mechanisms of action.